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Nutritional psychiatry is a growing area of research, with several nutritional factors implicated in the 
aetiology of psychiatric ill health. However, nutritional research is highly complex, with multiple 
potential factors involved, highly confounded exposures and small individual effect sizes. This paper 
considers whether Mendelian randomization provides a solution to these difficulties, by 
investigating causality in a low risk and low-cost way. Current studies using MR in nutritional 
psychiatry are reviewed, along with the potential opportunities and challenges of using this 
approach for investigating the causal effects of nutritional exposures. Several studies have identified 
potentially causal nutritional exposures using Mendelian randomisation in psychiatry, offering 
opportunities for further mechanistic research, intervention development, and replication. Using 
Mendelian randomisation as a foundation for intervention development allows the best use of 
resources in an emerging discipline in which opportunities are rich, but resources are often poor.  
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The founding of the International Society for Nutritional Psychiatry Research1 reflects an 
increasing recognition of nutrition as a modifiable risk factor for mental ill-health, and the need for 
good quality research in this area. Whilst the adverse psychological effects of severe nutritional 
deficiency are well established,2 the extent to which subtle nutritional factors might have on 
cognitive and affective processes, or on the increasing burden of psychological ill health at the 
population level remains unclear.  As wholefood diets have been replaced by processed foods - high 
in sugar and low in essential fats, vitamins and minerals - many argue that subtle malnutrition may 
exist even in the presence of calorie-abundance,3, 4 with unclear repercussions for population mental 
health. 5, 6 Several meta-analyses of prospective studies suggest that a high-quality diet can reduce 
the risk of mental illness,5, 6 warranting further investigation of specific nutritional factors and 
mechanisms. Conventional epidemiological associations between nutritional intake or status and 
psychiatric outcomes are highly prone to confounding by lifestyle and correlated dietary factors.7 
Furthermore, as many aspects of nutrition are affected by mental ill-health,8 it is likely that reverse 
causality, or at least a bi-directional relationship, explains some of these associations. Finally, as 
individual nutrients have small effect sizes, large sample sizes are required to explore such 
associations with adequate statistical power, in which accurate dietary measurement is difficult. 
Despite the best efforts of researchers to control for these limitations, nutritional epidemiology is 
limited by issues of residual confounding, biological complexities and limited power.  
Interventional research in nutritional psychiatry is a potential solution to these limitations, 
as good quality randomized controlled trials (RCTs) eliminate issues of confounding and reverse 
causality.  There are a growing number of RCTs in nutritional psychiatry. Although many studies have 
focused on individual nutritional supplements - probably reflecting the parallels with a 
pharmacological research model,9-11 there are few supplements that have been robustly identified as 
beneficial in psychiatry.11 Results are often inconsistent, and it is unclear which interventions are 




more comprehensive nutritional approach may be preferable. Combination micronutrient 
supplement interventions12-14 and interventions focused on making broader changes to dietary 
patterns might be advantageous.15, 16 Dietary pattern interventions offer a potential solution to this 
complexity, with supporting meta-analytical evidence in both observational5 and interventional 
research17. However, selecting the right intervention and participants, and accounting for behaviour 
change and attrition, make the planning and evaluation of such trials complex and costly. With a 
multitude of potential nutritional interventions, it can be difficult to prioritise the most likely to be 
effective. False negatives from underpowered designs or minor aberrations in a complex 
intervention, might hinder the development of potentially beneficial interventions. Conversely, false 
positives due to biased designs, compounded by publication bias, lead to wasted expenditure and 
potential harm in repeated trials. Further evidence to establish likely causality for specific nutritional 
factors to underpin nutritional interventions and identify the most likely beneficial components 
would prevent wasted time and expenditure. 
This paper considers whether ‘Mendelian randomization’ is a viable method to inform 
intervention development in nutritional psychiatry, in a low-cost and low-risk way. We review 
existing Mendelian randomization studies in nutritional psychiatry, the challenges faced, and 
opportunities for further research.  
 
MENDELIAN RANDOMIZATION 
Mendelian randomization (MR) is a method that is increasingly used to infer causality in 
epidemiological research. MR uses genetic markers that are robustly associated with a particular 
potentially modifiable exposure as ‘instrumental variables’ in assessing the relationship between an 
exposure and an outcome.18, 19 As genetic markers (or ‘alleles’) are randomly allocated at 
conception, many have compared MR to a natural RCT, in which variant alleles rather than 




as single nucleotide polymorphisms (SNPs). MR exploits this natural genetic variation to circumvent 
the problem of confounding and reverse causality (figure 1a).  
The concept of MR relies on key assumptions for validity (figure 1b). Whilst a comprehensive 
review of MR is beyond the scope of this review, some key terms used to describe aspects of MR 
studies relevant to this review are explained in Table 1. For more detail, see Zheng et al 201720 and 
the MR Dictionary.21 
There are potential benefits to applying MR methodology to nutritional psychiatry, as a 
cheap and powerful method for attributing causality to putative exposures, and it enables the 
exploration of multiple avenues for intervention development in a low-cost and low-risk way. This is 
particularly true with the development of two-sample MR, in which exposures and outcomes need 
not be measured in the same sample (figure 1c). Two-sample MR takes estimates of the SNP-
exposure association from a one population (for example a genome-wide association study (GWAS) 
of a nutritional exposure), and the SNP-outcome association from another (for example, a GWAS of 
a given psychiatric outcome). This allows for the possibility of utilising the increasing sample sizes 
provided by large psychiatric genetic consortia, without the need to access individual-level data on 
specific nutritional measures. Given the relatively small effect sizes, and modest genetic contribution 
to nutritional exposures, a two-sample MR methodology using large outcome samples should 
provide adequate power to investigate them. 
One advantage of MR is that, providing appropriate genetic instruments are available, it is 
theoretically possible to model the results of certain randomised trials, thereby reducing 
unnecessary potential harms and expenditure. One example in the context of nutritional 
epidemiology was given by a recent MR study to model the Selenium and Vitamin E Cancer 
Prevention Trial (SELECT) for prostate cancer, which was based on extensive epidemiological 
evidence at that time. The SELECT trial, randomised 35,533 men to use selenium supplementation, 
to investigate whether increasing selenium levels might prevent prostate cancer.22 The $114 million 




prostate cancer risk, it was likely to increase the risk of advanced prostate cancer and type 2 
diabetes mellitus. These results were replicated by MR, using genetic instruments for circulating 
selenium in the PRACTICAL consortium.23 Although retrospective, the MR study took a fraction of the 
financial and time burden of a trial, and more importantly avoided any potential harm to 
participants.23 
A comparison between MR and a naturalised RCT, has its limitations. Firstly, as genetic 
variants reflect lifetime exposures rather than short durations of therapeutic intervention, MR may 
produce a stronger effect than in the best approximation of a time-limited intervention. Conversely, 
individual adaptation to genotype may reduce the effect of the SNP on the exposure and so may 
underestimate the effect (also known as canalization (see table 1)). Rather than a replacement for 
RCTs, MR might be viewed as a foundation from which interventions for further development can be 
identified, in combination with epidemiology and basic science, also referred to as triangulation24 
(figure 2).   
MR may be particularly useful for a field such as nutritional psychiatry, in which many of the 
interventional trials have small to modest sample sizes. A well-powered MR study can be used to 
verify results in a potentially underpowered study, as well as to inform future studies. MR studies 
showing no evidence for a causal effect need careful consideration about whether it is possible to 
rule out a clinically significant effect based on the available parameters, and whether replication 
using updated background literature would be beneficial at a future date. This includes whether the 
methods and instruments are valid, power is adequate, and whether biological complexity might 
complicate results. This is particularly relevant in psychiatry, where diagnostic categorisation is yet 
to account for the diversity of symptoms and presentations categorized by a single ‘disorder’. 
Studies showing strong evidence for an effect need equal consideration before intervention 
development is considered, - such as how to increase the nutritional exposure in the desired way, 
whether participants are selected based on deficiency states, and whether supplementation might 





MENDELIAN RANDOMIZATION STUDIES IN NUTRITIONAL PSYCHIATRY 
We identified 26 studies using MR to investigate causality in nutritional psychiatry (Table 2). 
Many have investigated a single exposure or outcome, but some have investigated multiple 
exposures and outcomes within the same paper. The studies are broadly grouped into three main 
psychiatric outcomes - cognitive impairment and dementia, schizophrenia, and mood disorders. 
 
Dementia and Cognition 
We identified 17 studies using MR to investigate the causality of nutritional factors on 
dementia and cognitive outcomes. Evidence suggesting a protective effect of 25-hydroxyvitamin D 
(25(OH)D) in Alzheimer’s disease has been shown in two studies in the International Genomics of 
Alzheimer’s Project (IGAP) Cohort (OR 0·86 per SD increase in vitamin D, 95% CI 0·78 to 0·94),25, 26 
but not replicated in the Uppsala Longitudinal Study (Hazard ratio per allele 1.04, 95% CI 0.91 to 
1.19).27 Studies investigating 25(OH)D as a causal factor in cognitive function have found no evidence 
for an association.27-29 It may be that vitamin D is particularly relevant to Alzheimer’s pathology, or 
that larger sample size or stronger genetic instruments are required to identify the effects in non-
clinical population samples. Furthermore, a possible non-linear observational association between 
vitamin D and cognition, with both deficiency and excess associated with poor cognition, was noted 
by Maddock et al 2017.29 This raises important considerations about the ability of traditional MR 
techniques to detect causality for cognitive outcomes,29 as well as other associations in which a 
similar relationship has been noted.30 Novel methods are being developed to manage non-linearity 
in MR,31 but are not commonly employed.  
Studies investigating the causal role for B vitamin pathways in dementia have had mixed 
results. A study looking at multiple exposures using the IGAP cohort did not provide evidence for 
folate (OR 0·98 per SD, 95% CI 0·72 to 1·33), homocysteine (OR 0·99 per SD, 95% CI 0·88 to 1·11) or 




studies looking at homocysteine using a single SNP in the methylenetetrahydrofolate reductase 
(MTHFR) gene have suggested strong evidence of causality.33 The MTHFR gene produces an enzyme 
which activates folate to metabolise homocysteine, and SNPs in this gene have been identified in 
GWAS of both homocysteine and circulating folate levels. However, some have suggested caution in 
the use of the MTHFR gene for MR due to a complex interaction with folate intake, in which the 
same polymorphism leading to reduced enzymatic activity in low-intake states (and therefore low 
blood folate and high homocysteine), may not have any effect on blood folate or high homocysteine 
in high-intake states.34 Several MR studies of homocysteine using a single SNP relating to MTHFR 
have failed to replicate using instruments containing more SNPs and explaining a greater variation in 
homocysteine levels, suggesting that this SNP may be acting via a different mechanistic pathway. A 
meta-analysis of the results for homocysteine in Alzheimer’s disease using the different instruments 
suggests some causal evidence for homocysteine (pooled effect 1.34 per SD, 95% CI 1.03 to 1.66), 
but in light of the complex biology, this may be misleading. Another study investigating vascular 
dementia using the same single SNP in the MTHFR gene also showed strong causal evidence for  
homocysteine (OR 4·29 per SD log(homocysteine), 95% CI 1·11 to 16·57).35 However, the same 
caveats apply. 
A single identified study has investigated amino acids in psychiatric disease, suggesting a 
potential causal role for isoleucine in Alzheimer’s disease (OR 1·35 per SD, 95% CI 1.08 to 1.69), 
though not for other branched chain amino acids such as valine and leucine.36  
The established link between APOE genotype and Alzheimer’s has been corroborated using 
MR studies (OR 1.41 per mg/dL of APOE, 95% CI 1.27 to 1.57).37 Further exploration of the role of 
lipids in dementia have not shown evidence for a causal role for any specific lipid faction when the 
APOE SNPs are excluded from analysis.38, 39 MR studies investigating fasting glucose (OR 1·12 per SD, 
95% CI 0·97 to 1·30),40 and vitamin E levels (OR 0·96 per SD, 95% CI 0·47 to 1·94),41 have not found 




outcomes including Alzheimer’s disease found no causal evidence for magnesium (0.43 per SD, 95% 
CI 0.08 to 2.44), calcium (Ca 0·74 per SD, 95% CI 0·45 to 1·22), Iron (1·02 per SD, 95% CI 0·94 to 1·14) 
or zinc (0·99 per SD, 95% CI 0·85 to 1·14), with weak evidence for low copper (0·87 per SD, 95% CI 
0·75 to 1·00).42 
 
Schizophrenia 
We identified six studies that have investigated nutritional exposures in schizophrenia using 
MR. There was weak causal evidence for vitamin B6 (OR 0·99 per SD log(B6), 95% CI 0·65 to 1·51),43 
and for serum minerals (Calcium, Serum Magnesium, Copper, Iron and Zinc, see Table 2) in 
schizophrenia.42 Two studies have identified an association between homocysteine and 
schizophrenia, in European (2·15 per SD, 95% CI 1·39 to 3·32)44 and Japanese populations (1.14 per 
SD, 95% CI 1.03 to 1.27);45 however, both used a single SNP related to the MTHFR gene, with the 
aforementioned limitations. A study looking at the causal role of glucose and insulin related traits 
found some evidence for fasting glucose (OR 0·84 per SD, 95% CI 0·71 to 0·99), but strong evidence 
for fasting insulin levels (OR 2·33 per SD, 95% CI 1·40 to 3·90).46 Given the discrepancy with the 
strength of effect of fasting glucose in the same study, it is likely that insulin partially acts through an 
independent pathway to glucose, possibly related to a direct action as a ‘neuropeptide’, involved in 
neuroplasticity and modulation. 
In contrast to findings in multiple sclerosis47 and Alzheimer’s Disease,26, 27 no strong causal 
evidence has been found for vitamin D in schizophrenia (OR 0·99 per 10% increase in 25(OH)D, 95% 
CI 0·97 to 1·01).48 This may suggest that the observational estimate is the result of confounding or 
reverse causality, but it is also possible that standard MR techniques have been unable to detect a 
true causal association due to limited power, population stratification, or biological complexities 
(table 4). Although the power of the study appears more than adequate (example sample sizes 




vague, and more subject to symptom interpretation that for an outcome such as multiple sclerosis 
or Alzheimer’s Disease. This heterogeneity may require larger sample sizes to identify causal effects 
of a similar magnitude. A second limitation is MR results represent the causal impact of a lifetime 
exposure on an outcome, it is unable to account for exposures that are time-limited or during a 
sensitive period.  
For example, if the sensitive period for vitamin D deficiency is intrauterine, as suggested by 
the higher prevalence among winter-born individuals,49 an MR analysis would not reflect this. Finally, 
standard MR techniques assume a linear relationship between exposure and outcome, which in the 
case of vitamin D might be a fallacy, as both deficiency and excess states may be harmful.30 Standard 
MR techniques assume a linear association between the exposure and outcome, and whilst novel 
methods are being developed to overcome this limitation, they are not yet standard practice.31  
 
Mood Disorders 
Several nutritional factors have been investigated using MR in major depression samples, 
with no strong evidence of effect. Nutritional factors include vitamins  B12 and folate,50 omega 3 
fatty acids,51 and 25-hydroxyvitamin D.52 The five minerals investigated in Cheng 2019 did not show 
evidence of causality, though the Psychiatric Genomics Consortium sample used as the outcome is 
small (N=10,640) in comparison to the latest PGC Major Depression sample (N=807,553).42 An MR 
study using the Young Finns study 53 showed an inverse association between fasting glucose and 
depressive symptoms measured using the Beck Depression Inventory, (−0·43 BDI points per 
weighted effect allele, 95% CI −0·79 to 0·07), which the authors hypothesise to relate to the 
cognitive effects of hypoglycaemia. A study in UK Biobank suggested a potentially causal role for 
elevated triglycerides (but not LDL- or HDL-cholesterol) in the development of lifetime major 
depression (OR 1.18 per SD (1·09–1·27)).54  
An MR study looking at multiple minerals identified a potentially causal role for low copper 




66·26) in bipolar disorder using the Bipolar Disorder Working Group sample of the Psychiatric 
Genomics Consortium. Both findings warrant replication and further investigation. Some 
observational literature has suggested higher serum magnesium (though lower intracellular 
magnesium) levels in bipolar disorder, and the pathophysiological mechanisms behind this could be 
further explored using two-step MR (figure 3a). 
 
OPPORTUNITIES FOR MR IN NUTRITIONAL PSYCHIATRY 
Although one of the biggest challenges for MR in nutritional psychiatry to date has been the 
lack of appropriate genetic instruments, nutritional genetics is evolving. Instruments for many 
nutritional exposures are being utilised in MR studies outside psychiatry or applied to only one of a 
multitude of psychiatric outcomes. In addition to biological nutritional markers, GWAS of dietary 
intake,55 dietary patterns,56 and even gut microbial diversity,57 may provide useful potential 
instruments for future MR studies aiming to assess the impact of nutritional  characteristics on 
psychiatric ill-health. For example, evidence suggests that gut microbial diversity and abundance is 
influenced by human genetics,57 making MR studies of this exposure possible, with examples of 
causal relationships being identified using MR in other areas of medicine.58 MR studies of the gut 
microbiome characterised in different ways may help to explain the association between reduced 
gut microbiome diversity and the presence of specific bacterial taxa in psychiatric disease,59 and the 
apparent benefits of probiotics in psychiatry.60, 61  
MR methods are continually evolving (see table 1), with several techniques relevant to 
research in nutritional psychiatry. An example is multivariable MR (see figure 3b), which can be 
employed in situations where genetic variants are related to several correlated exposures. 
Multivariable MR has been used successfully in untangling the association between high density 
lipoprotein cholesterol, low density lipoprotein cholesterol, and triglycerides with cardiovascular 
disease62 and depression.54 Multivariable MR could similarly be used to unpick potentially complex 




positive findings in nutritional psychiatry, potential off-target adverse effects of nutritional 
supplementation could be identified using MR phenome-wide association study (MR-PheWAS).63 An 
MR-PheWAS uses a hypothesis-free approach to scan many outcomes for a given exposure, and 
could have potentially pre-empted the increased risk of diabetes with selenium supplementation 
seen in the SELECT trial.23 As well as informing intervention development, MR can also be used to 
investigate biological mechanisms in psychiatry including metabolomic, microbiomic, proteomic and 
epigenomic intermediates, using two-step MR.64 Two-step MR is a relatively new method for 
identifying and quantifying mediating mechanisms between an exposure and outcome using an MR 
framework (figure 3a). Novel MR methods to analyse gene-environment interactions are also under 
development, and may be particularly useful in the context of nutritional psychiatry. Finally, using 
MR of the human proteome in relation to psychiatric outcomes may identify novel drug targets.  
Standard MR methods rely on a single exposure-outcome framework, which many consider 
to be oversimplified when in the context of complex nutritional biology. Many nutritional 
epidemiologists have moved beyond a single nutrient approach to consider whole dietary patterns, 
adiposity, and the inherently complex interaction between diet, hormones and physical activity.65 It 
is possible that future MR methods could consider interactions between other nutritional exposures, 
as well as with gene-environment interactions considering nutritional intake or other lifestyle 
factors. Techniques such as machine learning and data mining using nutritional exposures, genetic 
data, dietary intake and psychiatric diagnoses and symptoms might be necessary for unpicking 
complex associations and gene-environment interactions further. Machine learning has already been 
suggested for augmenting MR, by predicting the most appropriate model to optimise power and 
detect pleiotropy, and could potentially enhance MR in the complex arena of nutritional 
psychiatry.66 
 




With increasing availability of genetic instruments, genetic samples, and platforms for MR 
analysis, false results can be obtained quickly. Results need careful consideration as to validity of the 
methods, samples, and instruments used, irrespective of their strength or direction. Subsequent 
replication in independent cohorts remains crucial.19  
Several limitations of traditional MR methods may hinder the application to nutritional 
psychiatry (see table 4). The lack of valid, robust genetic instruments for many nutritional exposures 
is arguably one of the most fundamental limitations. GWAS studies identifying SNPs robustly 
associated with nutritional exposures depend on adequately sized genotyped samples of nutritional 
factors. Difficulties identifying robust and reliable nutritional biomarkers reflecting nutritional status 
may underlie this, along with the availability of such nutritional measures in adequately sized 
genotyped cohorts. Instruments that are only weakly associated with the exposure of interest (e.g. 
F-statistic <10, see table 2) will bias estimates in different directions depending on whether a one-
sample or two-sample methodology is used (table 4). 
Nutritional genetic epidemiology is a developing field and the expectation is that good 
quality, validated instruments for nutritional exposures should emerge and evolve. However, even 
where genetic instruments appear to exist, some consideration needs to be given to whether they 
are valid for the specific association being tested with MR analyses, checking as far as possible that 
the assumptions of MR hold, and by understanding their underlying biological function. 
With the increasing development of large psychiatric genomics consortia samples, outcome 
sample sizes are rapidly increasing. At first glance these appear to provide ample power to detect 
nutritional exposures, even those with a very small effect (see table 3.)19 However, as sample sizes 
increase, it is important to consider the extent to which the genetic heterogeneity of the population 
has increased, and the validity of the genetic instrument within this new population structure. 
Furthermore, the risk of overlapping exposure and outcome samples may invalidate some of the 




measured nutritional exposures and psychiatric symptomatology, compared to large samples with 
imprecise measures and heterogenous samples are not always clearly defined. 
 
FUTURE DIRECTIONS 
Genetic epidemiology is evolving. Sample sizes, genetic markers and MR techniques are 
continuing to increase in both number and complexity. Negative early findings need careful 
consideration, and positive findings warrant replication in independent cohorts. As sample sizes and 
genetic instruments develop, formal repetition of earlier studies and independent replication 
remains essential. Given the relative ease with which analyses can be conducted once an instrument 
is identified, a more systematic and thorough approach to evaluating nutritional factors in psychiatry 
would be beneficial, perhaps considering individual psychiatric presentations along with a ‘cross-
disorder’ approach. Opportunities for undertaking GWAS of nutritional biomarkers should be sought 
and validated, to make future MR studies possible. Future MR studies should consider novel MR 
techniques such as multivariable MR where appropriate, techniques for accounting for non-linear 
associations, as well as two-step MR to identify causal mechanisms. Further understanding of gene-
environment interactions using large biobanks with data on genetics as well as nutritional and 
lifestyle measures might be useful for triangulating with nutritional MR studies. Finally, as the 
research landscape evolves, replication of earlier studies using larger samples and improved genetic 
instruments, continues to be of value.  
Beyond genetics, ongoing research from a broad range of disciplines including epidemiology, 
basic sciences, and clinical trials is needed to identify novel biomarkers of nutritional intake and 
status, to develop new technologies for accurate dietary assessment, and to apply the results of MR 






Nutritional psychiatry, nutritional genetic epidemiology and psychiatric genetics are all at 
relatively early stages in their understanding. MR in nutritional psychiatry sits at the centre of these 
emerging disciplines, providing a unique way to investigate causality in nutritional psychiatry and 
understand its mechanisms. Despite some challenges in this area, emerging MR evidence for 
nutritional factors including vitamin D, folate, serum magnesium, copper, triglycerides, and glucose 
metabolic pathways on psychiatric outcomes highlight the potential utility of this technique for 
identifying causal factors in nutritional psychiatry and developing a firm evidence base for the 
causality of nutritional exposures from which successful interventions can develop. 
 
SEARCH STRATEGY AND SELECTION CRITERIA  
References for this review were identified through systematic searches of OVID Medline 
(1946 to January 2019,) PsycINFO (1808 to January 2019) and EMBASE (1974-2019) database for 
articles published from by use of the terms “Mendelian randomization”, “Psychiatry OR Psychology”, 
and other diagnostic terms (see Appendix 1). All abstracts identified were screened to include any 
exposure related to nutrition. Exposures were included if they measured any factor that was directly 
related to nutritional components or nutritional status, including micronutrients (including vitamins 
and minerals), macronutrients (including glucose homeostatic markers, amino acids and peptides 
and lipids), and biological markers of nutritional status. These factors were not selected a priori, but 
identified post-hoc based on the MR exposures available. Studies using psychiatric diagnosis as an 
exposure rather than outcome, addressing broader lifestyle exposures such as body mass index, 
physical activity or alcohol, and considered inter-generational exposures (such as offspring outcomes 
of pregnancy exposures) were excluded. A full search strategy is given in Appendix 1, with a 





RESEARCH IN CONTEXT 
Evidence before this study 
Nutritional psychiatry is an emerging area of research, but its complexities are numerous. Several 
nutritional factors have been implicated in psychiatric aetiology, but causal evidence remains scarce. 
Mendelian randomization (MR) is an epidemiological method that can help investigate causality. 
Outside of psychiatry, MR has identified likely causal associations between low vitamin D and 
multiple sclerosis, low serum iron and Parkinson’s disease, and low serum magnesium and 
cardiovascular disease. We searched the OVID Medline database for studies using “Mendelian 
randomization” with any outcome related to “Psychiatry OR Psychology”. We excluded studies in 
which psychiatric conditions were used as an exposure rather than outcome, which used broader 
lifestyle exposures such as body mass index, physical activity or alcohol, and for which the exposure 
and outcome was inter-generational (such as offspring outcomes of pregnancy exposures).  
 
Added value of this study 
Several studies have investigated potential causal nutritional factors in psychiatry using MR. This 
study summarizes the current evidence and explores the opportunities and challenges in using this 
method to underpin intervention development. This paper also summarises some of the novel 
methods in MR, and how they might overcome issues with correlated nutritional exposures, non-
linear effects, and to identify potential harms of supplementation. 
 
Implications of all the available evidence 
Several MR studies have shown evidence for causal nutritional factors in psychiatry . A 
comprehensive approach to investigating nutritional exposures psychiatry would be beneficial for 
the current evidence base and would help to inform intervention development in a resource-




strength of evidence, and to replicate results as new samples, methods and biological insights 
become available. 
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Table 1: Glossary of MR Terms and potential uses in nutritional psychiatry 20 For more information 
about other terms and the  
Term Explanation 
F-Statistic The F-statistic measures the strength of genetic instruments. F<10 is 
suggestive of weak instrument bias. 






 MR PheWAS is a method using a hypothesis-free approach to scan many 
outcomes for a given exposure using MR methodology. Such approaches 
could be used to test for and identify any potential adverse off-target 
effects of dietary supplementation, providing genetic instruments exist. 
Pleiotropy Horizontal Pleiotropy is where the SNP or SNPs related to the exposure 
are associated with the outcome through a pathway independent of the 
exposure (i.e. a violation of assumption c in figure 1b). 
Pleiotropy can be demonstrated by several methods, including Cochran’s 
Q statistic testing heterogeneity in causal estimates from each SNP, MR-
Egger intercept, and leave-one-out analysis to identify influential outliers 
Population 
Stratification 
Spurious associations may arise in MR where the genetic variant and the 
outcome are associated with ancestral background in a mixed or 
stratified sample. Using genetic associations from within homogenous 
populations, or checking that the GWAS has controlled for population 
substructure in the analysis is important. 
One-sample MR Conventional one-sample MR uses a single sample in which exposure, 
outcome and genetic instrument are measured within the same 




sample sizes of studies that are required to have genotype, exposure and 
outcome data. 
Two-Sample MR The estimates of the SNP-exposure and SNP-outcome associations used 
in MR analyses are identified in independent studies (usually genome-
wide association studies) 
Two-Step/ 
Mediation MR 
Two-step MR can be used to identify mediating mechanisms between an 
exposure and outcome using two steps- the first to assess the causal 
effect of the exposure on the potential mediator, and the second to 




Table 2: Studies using Mendelian randomization in nutritional psychiatry 
Table summarizes current MR studies in nutritional psychiatry. Discrepancies exist between disorders, and the applicability of existing instruments to other 
outcomes, or to a combined ‘cross disorder’ cohort may be fruitful. Results are given as odds ratios per standard deviation change in the exposure unless 
otherwise specified. Abbreviations: IGAP (International Genomics of Alzheimer’s), Psychiatric Genomics Consortium (PGC). For further details of instrument rsids, 




                                                          
1 IGAP International Genomics of Alzheimer’s Project 
2 PGC Psychiatric Genomics Consortium  
 
 
Exposure Study Measure Sample  N MR Method SNPs Results Reported  
OR / beta/ Hazard ratio/ Risk difference 
(95% confidence intervals) p-value 
         








Maddock 2017 29 Global Cognitive tests  Cross cohort  172,349 Two-sample  2 β 0.00 points per 25(OH)D decreasing 
allele (0.01, 0.01) p>0.99 
Memory tests  β 0.00  points per 25(OH)D decreasing 
allele  (-0.01, 0.01) p=0.6 
Jorde 2015 28 Cognitive Tests  Tromso Study 5,980 One-sample  4 No overall association 
Mokry 2016 25 Alzheimer’s Diagnosis IGAP1 54,162 Two-sample  4 OR 0.8 per SD (0.97, 0.66) p=0.021  
Olsson 2017 27 Dementia Diagnosis Uppsala 
Longitudinal 
Study 




408 One-sample 2 OR 1.03 per effect allele (0.80, 1.34) 
Larsson 2018 26 Alzheimer’s Diagnosis IGAP 54,162 Two-sample  7 OR 0.86 per SD (0.78, 0.94) p = 0.002 
Taylor 2016 48 Schizophrenia Diagnosis PGC2 79,845 Two-sample  4 OR 0.99 per 10% increase (0.97, 1.0) 




                                                          
3 SLCR90_r diagnosis depression… 
        
Vitamin E Liu 2018 41 Alzheimer’s Diagnosis IGAP 54,162 Two-sample  3 OR 0·96 per SD (0·47,1·94) p =0·936 
        
Vitamin B6 Tomioka 2018 43 Schizophrenia Diagnosis Tokushima 
University 
Hospital 
10,689 One-sample 1  OR 0·99 per SD log(B6)  (0·65, 1·51) p= 
0·96 
        
Folate  Larsson 2017 32 Alzheimer’s Diagnosis IGAP 54,162 Two-sample 2 OR 0·98 per SD (0·72, 1·33) p=0·89 
Mollehave 2017 50 Depression (SLCR90_r3) Health 2006 & 
Inter 99  
4,126 One-sample  2  OR 1·18 per effect allele (0·18, 7·66), 
P=0·86 
        
Homocysteine Hu 2016 33 Alzheimer’s Diagnosis 34 studies 9,397 Two-Sample  1   OR 3·37 per SD ( 1·90, 5·95) p = 2·9×10-5 
Larsson 2017 32 Alzheimer’s Diagnosis IGAP 54,162 Two-sample 18 OR 0·99 per SD (0·88, 1·11) 0·86 
Roostaei 2018 67 Alzheimer’s Diagnosis IGAP 54,162 Two-sample  13  OR 1·01 per SD (0·89, 1·15), p=0·84 
Numata 2015 44 Schizophrenia Diagnosis 36 Studies 25,599 Two-sample  1 OR 2·15 per SD (1·39, 3·32) p=5·3x10−4 
Kinoshita 201545 Schizophrenia Diagnosis Meta-analysis 10,378 One-sample 1 OR 1.14 per SD (1.03-1.27), p=1.6x10-2 
Wu 201735 Vascular Dementia 
Diagnosis 
Meta-analysis  1,880 Two-sample  1 OR 4·29 per SD log (hcy) (1·11,16·57) P = 
0·03 




                                                          
4 SLCR90_r diagnosis depression… 
B12 Mollehave 2017 50 Depression (SLCR90_r4) Health 2006 & 
Inter 99  
4,126 One-sample  12  0·96 (0·52,1·79), P=0·91 
Larsson 2018 32 Alzheimer’s Diagnosis IGAP 54,162 Two-sample 7 OR 1·11 per SD (0·95, 1·30) p=0·18 






Calcium Cheng 201942 Alzheimer’s Diagnosis IGAP 54,162 Two- 
sample  
6 OR 0·74 per SD (0·45, 1·22) p=0·23 
Major Depression Diagnosis PGC  10,640 Two- 
sample  
6 OR 0·92 per SD (0·67, 1·28) p=0·63 
Bipolar Disorder Diagnosis PGC 41,653 Two- 
sample  
7 OR 1·85 per SD (0·74, 4·65) p=0·19 
Schizophrenia Diagnosis PGC 65,967 Two- 
sample 
7 OR 1·85 per SD (0·74, 4·65) p=0·19 
        
Copper Cheng 201942 Alzheimer’s Diagnosis IGAP 54,162 Two- 
sample  
2 OR 0·87 per SD (0·75, 1·00) p=0·05 
Bipolar Disorder Diagnosis PGC 41,653 Two- 
sample  
2 OR 0·87 per SD (0·79, 0·97) p=0·01 
Schizophrenia Diagnosis PGC 65,967 Two- 
sample 




        
Magnesium Cheng 201942 Alzheimer’s Diagnosis IGAP 54,162 Two- 
sample  
4 OR 0·43 per SD (0·08-2·44) p=0·34 
Major Depression Diagnosis PGC  10,640 Two- 
sample  
3 OR 1·19 per SD (0·22, 6·61) p=0·84 
Bipolar Disorder Diagnosis PGC 41,653 Two- 
sample  
4 OR 8·78 per SD (1·16, 66·26) p=0·04 
Schizophrenia Diagnosis PGC 65,967 Two- 
sample 
4 OR 0·87 per SD (0·24, 3·19) p=0·83 
        
Iron Cheng 201942 Alzheimer’s Diagnosis IGAP 54,162 Two- 
sample  
11 OR 1·02 per SD (0·94, 1·14) p=0·48 
Major Depression Diagnosis PGC   10,640 Two- 
sample  
9 OR 0·98 per SD (0·91, 1·05) p=0·60 
Bipolar Disorder Diagnosis PGC 41,653 Two- 
sample  
11 OR 1·17 per SD (0·89, 1·29) p=0·45 
Schizophrenia Diagnosis PGC 65,967 Two- 
sample 
10 OR 1·04 per SD (0·92, 1·18) p=0·55 




Zinc Cheng 201942 Alzheimer’s Diagnosis IGAP 54,162 Two- 
sample  
 2 OR 0·99 per SD (0·85, 1·14) p=0·85 
Major Depression Diagnosis PGC 10,640 Two- 
sample  
2 OR 0·99 per SD (0·95, 1·03) p=0·66 
Bipolar Disorder Diagnosis PGC 41,653 Two- 
sample  
2 OR 1·02 per SD (0·91, 1·14) p=0·70 
Schizophrenia Diagnosis PGC 65,967 Two- 
sample 
2 OR 0·94 per SD (0·86, 1·02) p=0·11 

















Isoleucine Larsson 2017 36 Alzheimer’s Diagnosis IGAP 54,162 Two-sample  
  
4  OR 1·35 per SD (1·08,1·69) p=0·007 
Leucine 1  OR 1·16 per SD (95% CI, 0·78–1·72) 
p=0·46 
Valine 1 OR 1·13 per SD (95% CI, 0·82–1·57 
p=0·46 
        
Fasting Glucose Weslowska 2017 53 Depression (BDI) Young Finns 
Study  
1,217 One-Sample  35 -0·43 (-0·79, -0·07) p=0·02 
Li 2018 46 Schizophrenia Diagnosis PGC  77,096 Two-sample  30 OR 0·84 per SD, (0·71,0·99) p=0·038 
BIO-X 26,026 14 OR 1·04 per SD (0·84,1·27) p=0·737 




        
Fasting insulin and 
insulin sensitivity 
Ostegaard 201540 Alzheimer’s Diagnosis IGAP 54,162 Two-sample  10 OR 1·32 per SD (0·88, 1·98) p=0.18  
Walter 2016 68 Alzheimer’s Diagnosis IGAP 54,162 Two-sample 9 OR 1·17 per unit (1·02,1·34) p=0.02 
Li 2018 46 Schizophrenia Diagnosis PGC  77,096 Two-sample  13 OR 2·33 per SD (1·40, 3·90) p=0.001 
        
DHA (Omega 3)  Sallis 2014 51 Perinatal  Depression 
(EPDS) 
ALSPAC mothers 2,378 One-sample 4  RD 0·08 (-0·05, 0·22) p=0·21 
        




City Heart Study 
106,562 One-sample 5 OR 1.41 per mg/dL (1.27, 1.57)  
All Dementia OR 1.33 per mg/dL (1.25, 1.43) 
        
Cholesterol & 
Triglycerides 






Alzheimer’s Diagnosis Cross Cohort  10,578 Two-Sample  70  OR 0·95 per unit (0·76,1·21) p=0·69 Total 
Cholesterol 
40 OR 1·10 per unit (0·89,1·37) p=0·36  
Triglycerides 
69 1·01 per unit (0·82,1·24) p=0·96  HDL-c 





       
Ostergaard 201540 Alzheimer’s Diagnosis  IGAP 54,162 Two-sample   73  OR 1·94 per SD (1·79-2·10) p=3·1x10-56 
Total Cholesterol 
 39  OR 0·96 per SD (0·87,1·07) p=0·48 
Triglycerides 
71 OR 0·75 per SD (0·69, 0·82) p=1x10-11 
HDL-c 
57 OR 2·31 per SD (2·12, 2·50) p=3x10-87 
LDL-c 
       




City Heart Study 
111,194 One-sample 380 OR 0·57 per mmolL-1 (0·27, 1·17) LDL-c 
Vascular Dementia  OR 0·81 per mmolL-1  (0·34, 1·89) LDL-c 
All Dementia  OR 0·66  per mmolL-1  (0·34, 1·26) LDL-c 
       
Khandaker 201954 
 
Major Depression UK Biobank 367,703 Two-sample 76 OR 1.02 per SD (0.91–1.14) LDL-c 
86 OR 0.97 per SD (0.91–1.03) HDL-c 










Table 3: A rough guide to sample size requirements for MR studies 
An illustration of minimum sample sizes required for MR studies, taken from the online calculator 
available at http://cnsgenomics.com/shiny/mRnd/ 69 Results shown are for a binary outcome, 
assuming 25% cases in study, 0.8 power and alpha 0.05.  
Variance explained Estimated Effect Size 
(OR) 
Minimum Sample size 
   




   











Table 4: Limitations of MR 20 











certain exposures  












Choose a proxy exposure for which 
data is available. Continue to review 





that are weakly 
associated with 
an exposure (e.g. 
F-statistic <10) 












as well as having 
Increase sample sizes (e·g· through 
publicly available GWAS datasets and 
consortia). 
Explain more variation in the 




sample MR, and 







Low Power May be caused by 
small sample size, 
low variance 
explained in the 
exposure by the 
SNP, confounding 
and type 1 error 
rate. 
Inadequate 
power may result 
in null results and 
hinder important 
further research. 
Increase sample size or instrument 
strength where possible 
Power for one-sample MR can be 









and the outcome 
of interest goes 
through an 
alternative 
pathway to the 
exposure. 
Violates a core 
assumption of 
MR (figure 1c). 
Understand underlying biological 
function of genetic variants. 
Use variants directly coding for 
exposure of interest where possible. 





alleles in close 
Confounding can 
be introduced by 
using an allele 













Utilise genetic alleles on separate 
chromosomes  
Use homogeneous populations where 





adaptation to a 
genetic change, 
which reduces the 
phenotypic effect 
of the genetic 
change·  
 MR may produce 
causal estimates 





The extent of the impact of 





may result from 
using mixed 
populations in 
which the genetic 
variant and 
outcome are 





vitamin D in 
schizophrenia. 
Use genetic associations derived from 
within homogenous populations only· 
Use summary results statistics that 
have adequately controlled for 
population substructure through e.g. 
principal components analysis or 
linear mixed models. 
Biological 
Complexity 
MR may give 
misleading results 
Several studies 
have suggested a 


















not able to 
detect this. 


















Appendix 1: Search Strategy 
Papers included in this review were identified using the following search strategy (adapted from the 
Cochrane Mental disorders search strategy at https://cmd·cochrane·org/search-strategies-
identification-studies), executed on 5th May 2019. Modified MeSH terms were used for EMBASE/ 
PsychINFO databases· 
1. EATING DISORDERS/ or ANOREXIA NERVOSA/ or BINGE-EATING DISORDER/ or BULIMIA 
NERVOSA/ or FEMALE ATHLETE TRIAD SYNDROME/ or PICA/ 
2. HYPERPHAGIA/ or BULIMIA/ 
3. SELF-INJURIOUS BEHAVIOR/ or SELF MUTILATION/ or SUICIDE/ or SUICIDAL IDEATION/ or 
SUICIDE, ATTEMPTED/ 
4. MOOD DISORDERS/ or AFFECTIVE DISORDERS, PSYCHOTIC/ or BIPOLAR DISORDER/ or 
CYCLOTHYMIC DISORDER/ or DEPRESSIVE DISORDER/ or DEPRESSION, POSTPARTUM/ or 
DEPRESSIVE DISORDER, MAJOR/ or DEPRESSIVE DISORDER, TREATMENT-RESISTANT/ or 
DYSTHYMIC DISORDER/ or SEASONAL AFFECTIVE DISORDER/ 
5. NEUROTIC DISORDERS/ 
6. DEPRESSION/ 
7. ADJUSTMENT DISORDERS/ 
8. exp ANTIDEPRESSIVE AGENTS/ 
9. ANXIETY DISORDERS/ or AGORAPHOBIA/ or NEUROCIRCULATORY ASTHENIA/ or OBSESSIVE-
COMPULSIVE DISORDER/ or OBSESSIVE HOARDING/ or PANIC DISORDER/ or PHOBIC 
DISORDERS/ or STRESS DISORDERS, TRAUMATIC/ or COMBAT DISORDERS/ or STRESS 
DISORDERS, POST-TRAUMATIC/ or STRESS DISORDERS, TRAUMATIC, ACUTE/ 
10. ANXIETY/ or ANXIETY, CASTRATION/ or KORO/ 
11. ANXIETY, SEPARATION/ 
12. PANIC/ 
13. exp ANTI-ANXIETY AGENTS/ 
14. SOMATOFORM DISORDERS/ or BODY DYSMORPHIC DISORDERS/ or CONVERSION 
DISORDER/ or HYPOCHONDRIASIS/ or NEURASTHENIA/ 
15. HYSTERIA/ 
16. MUNCHAUSEN SYNDROME BY PROXY/ or MUNCHAUSEN SYNDROME/ 
17. FATIGUE SYNDROME, CHRONIC/ 
18. OBSESSIVE BEHAVIOR/ 
19. COMPULSIVE BEHAVIOR/ or BEHAVIOR, ADDICTIVE/ 
20. IMPULSE CONTROL DISORDERS/ or FIRESETTING BEHAVIOR/ or GAMBLING/ or 
TRICHOTILLOMANIA/ 
21. STRESS, PSYCHOLOGICAL/ or BURNOUT, PROFESSIONAL/ 
22. SEXUAL DYSFUNCTIONS, PSYCHOLOGICAL/ or VAGINISMUS/ 
23. ANHEDONIA/ 
24. AFFECTIVE SYMPTOMS/ 
25. *MENTAL DISORDERS/ 
26. (eating disorder* or anorexia nervosa or bulimi* or binge eat* or (self adj (injur* or 
mutilat*)) or suicide* or suicidal or parasuicid* or mood disorder* or affective disorder* or 
bipolar i or bipolar ii or (bipolar and (affective or disorder*)) or mania or manic or 
cyclothymic* or depression or depressive or dysthymi* or neurotic or neurosis or 
adjustment disorder* or antidepress* or anxiety disorder* or agoraphobia or obsess* or 




somatoform or somati#ation or medical* unexplained or body dysmorphi* or conversion 
disorder or hypochondria* or neurastheni* or hysteria or munchausen or chronic fatigue* 
or gambling or trichotillomania or vaginismus or anhedoni* or affective symptoms or 
mental disorder* or mental health)·ti· 
27. Schizophrenia/ or schizophrenia·mp·  
28. depression·mp· or Depression/ 
29. major depressive disorder·mp· or Depressive Disorder, Major/  
30. dementia·mp· or Dementia/ or Frontotemporal Dementia/ or Dementia, Vascular/ or 
Dementia, Multi-Infarct/  
31. autism·mp· or Autistic Disorder/  
32. eating disorder·mp· or "Feeding and Eating Disorders"/  
33. Borderline Personality Disorder/ or Mental Disorders/ or borderline personality·mp· or 
Personality Disorders/ 
34. psychosis·mp· or Psychotic Disorders/ 
35. exp "psychiatry and psychology (non mesh)"/ or psychiatry/ 
36. Attention Deficit Disorder with Hyperactivity/ or ADHD.mp./ or "attention deficit and 
disruptive behavior disorders"/ or child behavior disorders/ 
37. neurodevelopmental disorder.mp. or Neurodevelopmental Disorders/  
38. communication disorders/ or language disorders/ or dyslexia/ or language development 
disorders/ or speech disorders/ or learning disorders/ or intellectual disability/ 
39. Developmental Disabilities/ or Motor Skills Disorders/ or motor delay.mp. 
40. 1 OR 2 OR 3 OR 4 OR 5 OR 6 OR 7 OR 8 OR 9 OR 10 OR 11 OR 12 OR 13 OR 14 OR 15 OR 16 
OR 17 OR 18 OR 19 OR 20 OR 21 OR 22 OR 23 OR 24 OR 25 OR 26 OR 27 OR 28 OR 29 OR 30 
OR 31 OR 32 OR 33 OR 34 OR 35 OR 36 OR 37 OR 38 OR 39 
41. mendelian adj2 random* 
42. Mendelian Randomization Analysis/ or mendelian randomization·mp· 
43. instrumental adj2 variable 
44. 41 OR 42OR 43 














Appendix 2: Flow chart for identification and inclusion of studies· (Numbers for inclusion do not 








Appendix 3: Excluded papers 
The following papers were identified in the search strategy as potentially relevant. Reasons for 
exclusion from the current review is given where appropriate.  
 Paper Justification 
for exclusion 




1 Arafat, S. and C. C. Minica (2018). "Fetal origins of mental disorders? An 
answer based on Mendelian randomization." Twin Research and Human 
Genetics 21(6): 485-494. 
Exposure 
(birth weight) 
2 Belbasis, L., et al. (2018). "Risk factors and peripheral biomarkers for 
schizophrenia spectrum disorders: An umbrella review of meta-analyses." 
Acta Psychiatrica Scandinavica 137(2): 88-97. 
Review 
3 Benn, M., et al. "Low LDL cholesterol, PCSK9 and HMGCR genetic variation, 
and risk of Alzheimer's disease and Parkinson's disease: Mendelian 
randomisation study." BMJ 357: j1648. 
Included 
4 Benn, M., et al. (2018). "Glucose and risk of Alzheimer's dementia, vascular 




5 Bjorngaard, J. H., et al. (2015). "Association of body mass index with 
depression, anxiety and suicide - An instrumental variable analysis of the 
HUNT study." PLoS ONE 10 (7) (no pagination)(e0131708). 
Exposure 
(BMI) 
6 Bonilla, C., et al. "Maternal and offspring fasting glucose and type 2 
diabetes-associated genetic variants and cognitive function at age 8: a 
Mendelian randomization study in the Avon Longitudinal Study of Parents 
and Children." BMC Medical Genetics 13: 90. 
Maternal/ 
Offspring 
7 Bonilla, C., et al. "Vitamin B-12 status during pregnancy and child's IQ at 
age 8: a Mendelian randomization study in the Avon longitudinal study of 
parents and children." PLoS ONE [Electronic Resource] 7(12): e51084. 
Maternal/ 
Offspring  
8 Byrne, E., et al. (2019). "Investigating Causal Relationships between Major 
Depressive Disorder and Genetically Correlated Traits Using Mendelian 








9 Byrne, E. M., et al. "Inference in Psychiatry via 2-Sample Mendelian 
Randomization-From Association to Causal Pathway?" JAMA Psychiatry 
74(12): 1191-1192. 
Review 
10 Caramaschi, D., et al. "Exploring a causal role of DNA methylation in the 
relationship between maternal vitamin B12 during pregnancy and child's 
IQ at age 8, cognitive performance and educational attainment: a two-step 




11 Chekroud, A. M. (2019). "A Mendelian Randomization Approach for 
Assessing the Relationship Between Physical Activity and Depression." 




12 Cheng, W. W., et al. (2019). "Mineral Nutrition and the Risk of Chronic 
Diseases: A Mendelian Randomization Study." Nutrients 11(2): 12. 
Included 
13 Choi, K. W., et al. (2019). "Assessment of Bidirectional Relationships 
Between Physical Activity and Depression Among Adults: A 2-Sample 




14 Clarke, T.-K., et al. (2017). "Investigating shared aetiology between type 2 
diabetes and major depressive disorder in a population based cohort." 




15 Cornelis, M. C. and M. R. Munafo (2018). "Mendelian Randomization 







16 Cruchaga, C., et al. (2012). "Cerebrospinal fluid APOE levels: An 
endophenotype for genetic studies for Alzheimer's disease." Human 
Molecular Genetics 21(20): 4558-4571. 
Exposure (CSF 
proteins) 
17 Fluegge Ba, K. "Zinc and Copper Metabolism and Risk of Autism: a reply to 
Sayehmiri et al." Iranian Journal of Child Neurology 11(3): 66-69. 
Methods (not 
MR) 
18 Fluegge, K. (2016). "A reply to Wang T, Shan L, Du L, Feng J, Xu Z, Staal WG, 
Jia F. Serum concentration of 25-hydroxyvitamin D in autism spectrum 
disorder: a systematic review and meta-analysis. Eur Child Adolesc 
Psychiatry. 2015; doi: 10.1007/s00787-015-0786-1." European Child and 
Adolescent Psychiatry 25(4): 453-454. 
Response 
19 Fluegge, K. (2017). "Zinc and copper metabolism and risk of autism: A reply 
to Sayehmiri et al." Iranian Journal of Child Neurology 11(3): 66-69. 
Response 
20 Frangou, S., et al. (2019). "Insulin resistance: Genetic associations with 
depression and cognition in population based cohorts." Experimental 
Neurology 06: 06. 
Methods (non-
MR) 
21 Giltay, E. J., et al. (2009). "Serum cholesterol, apolipoprotein E genotype 
and depressive symptoms in elderly European men: The FINE study." 
Journal of Affective Disorders 115(3): 471-477. 
Included 
22 Grant, W. B. (2017). "Vitamin D and incident dementia and cognitive 
impairment." American Journal of Clinical Nutrition 106(2): 699-700. 
Response 
23 Hamer, M., et al. (2016). "Depressive symptoms and obesity: Instrumental 
variable analysis using mother-offspring pairs in the 1970 British Cohort 
Study." International Journal of Obesity 40(11): 1789-1793. 
Exposure 
(obesity) 
24 Hannon, E., et al. (2019). "Pleiotropic Effects of Genetic Variation 
Associated with Psychiatric Disorders on DNA Methylation." European 




25 Harbord, R. M., et al. (2010). "Genetically determined adiposity and 
reduced risk of common mental disorder. the copenhagen general 
population study with 53,221 participants." American Journal of 
Epidemiology 11): S52. 
Exposure 
(adiposity) 
26 Harbord, R. M., et al. (2011). "Using genetic loci to understand the 
relationship between adiposity and psychological distress: A Mendelian 
Randomization study in the Copenhagen General Population Study of 
53221 adults." Journal of Internal Medicine 269(5): 525-537. 
Exposure 
(adiposity) 
27 Hartwig, F. P., et al. (2016). "Body mass index and psychiatric disorders: a 
Mendelian randomization study." Scientific Reports 6: 32730. 
Exposure 
(BMI) 
28 Hu, Q., et al. (2016). "Homocysteine and Alzheimer's disease: Evidence for 
a causal link from Mendelian randomization." Journal of Alzheimer's 
Disease 52(2): 747-756. 
Included 
29 Hung, C. F., et al. (2014). "Relationship between obesity and the risk of 
clinically significant depression: Mendelian randomisation study." British 
Journal of Psychiatry 205(1): 24-28. 
Exposure 
(obesity) 
30 Jiang, L., et al. (2019). "Constrained instruments and their application to 
Mendelian randomization with pleiotropy." Genetic Epidemiology 12: 12. 
Review 
31 Jokela, M., et al. (2012). "Body mass index and depressive symptoms: 
Instrumental-variables regression with genetic risk score." Genes, Brain & 
Behavior 11(8): 942-948. 
Exposure 
(BMI) 
32 Jorde, R., et al. (2015). "Vitamin D and cognitive function: The Tromso 





33 Khandaker, G. M., et al. (2019). "Shared mechanisms between coronary 
heart disease and depression: findings from a large UK general population-
based cohort." Molecular Psychiatry 19: 19. 
Included 
34 Kinoshita, M. (2015). "One-carbon Metabolism and Schizophrenia. 
[Japanese]." Seishin shinkeigaku zasshi = Psychiatria et neurologia Japonica 
117(5): 362-368. 
Included 
35 Kivimaki, M., et al. (2011). "Does obesity really protect against 
psychological distress? Examining the 'fat-jolly' versus 'fat-sad' hypotheses 




36 Kivimaki, M., et al. (2011). "Examining Overweight and Obesity as Risk 
Factors for Common Mental Disorders Using Fat Mass and Obesity-
Associated (FTO) Genotype-Instrumented Analysis." American Journal of 
Epidemiology 173(4): 421-429. 
Exposure 
(obesity) 
37 Koshy, B., et al. (2010). "Genetic deficiency of plasma lipoprotein-
associated phospholipase A <inf>2</inf> (PLA2G7 V297F null mutation) 





38 Kubzansky, L. D., et al. (2015). "Revisiting mendelian randomization studies 
of the effect of body mass index on depression." American Journal of 
Medical Genetics, Part B: Neuropsychiatric Genetics 168(2): 108-115. 
Exposure 
(BMI) 
39 Kumari, M., et al. "Alcohol consumption and cognitive performance: a 
Mendelian randomization study." Addiction 109(9): 1462-1471. 
Exposure 
(alcohol) 
40 Kunutsor, S. K., et al. "Genetically elevated gamma-glutamyltransferase 
and Alzheimer's disease." Experimental Gerontology 106: 61-66. 
Exposure (iver 
enzymes) 
41 Kuzma, E., et al. (2017). "A systematic review of mendelian randomization 
studies investigating causal associations between risk factors and 
dementia." Alzheimer's and Dementia 13 (7): P1180. 
Review 
42 Kuzma, E., et al. (2018). "Which Risk Factors Causally Influence Dementia? 
A Systematic Review of Mendelian Randomization Studies." Journal of 
Alzheimer's Disease 64(1): 181-193. 
Review 
43 Kwok, M. K., et al. "Habitual coffee consumption and risk of type 2 
diabetes, ischemic heart disease, depression and Alzheimer's disease: a 




44 Larsson, S. C., et al. "Modifiable pathways in Alzheimer's disease: 
Mendelian randomisation analysis." BMJ 359: j5375. 
Included 
45 Larsson, S. C., et al. (2018). "Serum Parathyroid Hormone, 25-
Hydroxyvitamin D, and Risk of Alzheimer's Disease: A Mendelian 
Randomization Study." Nutrients 10(9): 06. 
Included 
46 Lauritzen, L., et al. "Mendelian randomization shows sex-specific 
associations between long-chain PUFA-related genotypes and cognitive 
performance in Danish schoolchildren." American Journal of Clinical 




47 Lawlor, D. A., et al. "Using genetic loci to understand the relationship 
between adiposity and psychological distress: a Mendelian Randomization 
study in the Copenhagen General Population Study of 53,221 adults." 
Journal of Internal Medicine 269(5): 525-537. 
Exposure 
(adiposity) 
48 Lehmann, D. J. and M. Cortina-Borja (2019). "Genetic influence of plasma 
homocysteine on Alzheimer's disease." Neurobiology of Aging 76: 217-218. 
Review 
49 Lewis, S. J., et al. "Maternal iron levels early in pregnancy are not 






randomization study." European Journal of Clinical Nutrition 68(4): 496-
502. 
50 Li, Z., et al. (2018). "Glucose and Insulin-Related Traits, Type 2 Diabetes 
and Risk of Schizophrenia: A Mendelian Randomization Study." 
EBioMedicine 34: 182-188. 
Included 
51 Ligthart, S., et al. "Genome Analyses of >200,000 Individuals Identify 58 
Loci for Chronic Inflammation and Highlight Pathways that Link 
Inflammation and Complex Disorders." American Journal of Human 
Genetics 103(5): 691-706. 
Exposure 
(CRP) 
52 Liu, G., et al. (2018). "Circulating vitamin E levels and Alzheimer's disease: 
A Mendelian randomization study." Neurobiology of Aging 72: 189. 
Included 
53 Lund, I. O., et al. (2019). "Is the association between maternal alcohol 
consumption in pregnancy and pre-school child behavioural and emotional 
problems causal? Multiple approaches for controlling unmeasured 
confounding." Addiction 08: 08. 
Maternal/ 
offsping 
54 Mack, S., et al. "Evaluating the Causal Relation of ApoA-IV with Disease-
Related Traits - A Bidirectional Two-sample Mendelian Randomization 






55 Maddock, J., et al. (2017). "Vitamin D and cognitive function: A Mendelian 
randomisation study." Sci Rep 7(1): 13230. 
Included 
56 Mejia-Guevara, I., et al. (2013). "The causal effect of obesity on anxiety: 




57 Michaelsson, K., et al. (2018). "Serum 25-Hydroxyvitamin D Concentrations 
and Major Depression: A Mendelian Randomization Study." Nutrients 
10(12): 15. 
Included 
58 Mokry, L. E., et al. (2016). "Genetically decreased Vitamin D and risk of 
Alzheimer disease." Neurology 87(24): 2567-2574. 
Included 
59 Mollehave, L. T., et al. (2017). "Association studies of genetic scores of 
serum vitamin B12 and folate levels with symptoms of depression and 
anxiety in two danish population studies." European Journal of Clinical 
Nutrition 71(9): 1054-1060. 
Included 
60 Mukherjee, S., et al. (2015). "Genetically predicted body mass index and 
Alzheimer's disease-related phenotypes in three large samples: Mendelian 
randomization analyses." Alzheimer's and Dementia 11(12): 1439-1451. 
Exposure 
(BMI) 
61 Murray, J., et al. (2016). "Moderate alcohol drinking in pregnancy 
increases risk for children's persistent conduct problems: Causal effects in 
a Mendelian randomisation study." Journal of Child Psychology and 
Psychiatry 57(5): 575-584. 
Maternal/ 
Offspring 
62 Nigg, J. T., et al. (2016). "Variation in an iron metabolism gene moderates 
the association between blood lead levels and attention-





63 Nishi, A., et al. (2014). "Meta-analyses of blood homocysteine levels for 
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